Haisco Pharmaceutical Group Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Researchers at Inventisbio ...

The most advanced internally discovered Eikon drug candidate is EIK1005. This drug is an inhibitor of WRN, an enzyme that plays a role in DNA damage repair. WRN has emerged as a therapeutic target ...

Eikon also has a few early stage pipeline features in the works, including two androgen receptor antagonists and internally derived WRN inhibitor to act as potential therapies for patients with ...

Haisco Pharmaceutical Group Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Eikon’s early-stage pipeline houses two androgen receptor antagonists and a WRN inhibitor dubbed EIK1005, which is being studied for its potential as a therapy for patients with microsatellite ...

Next in line is EIK1003, a highly selective PARP1 inhibitor acquired from China-based ... receptor antagonists and an internally developed WRN inhibitor that the biotech hopes could be aimed ...

In addition, Eikon’s early-stage pipeline features two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) that is being studied for its potential as a therapy for ...

Nimbus' pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in development for microsatellite instability high (MSI-H) tumors, as well as a diverse portfolio of preclinical ...